Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015, Article ID 917670, 11 pages
http://dx.doi.org/10.1155/2015/917670
Research Article

The Inhibitory Effect of Kakkonto, Japanese Traditional (Kampo) Medicine, on Brain Penetration of Oseltamivir Carboxylate in Mice with Reduced Blood-Brain Barrier Function

1Faculty of Pharmaceutical Sciences, Josai International University, 1 Gumyo, Togane, Chiba 283-8555, Japan
2Faculty of Pharmaceutical Sciences, Josai University, 1-1 Keyakidai, Sakado, Saitama 350-0295, Japan
3Onko-Do Kampo Akebono Yakkyoku Co., Ltd., 1-3-10 Gakuenhigashi-cho, Kodaira, Tokyo 187-0043, Japan

Received 30 September 2014; Revised 30 January 2015; Accepted 31 January 2015

Academic Editor: Nobuo Yamaguchi

Copyright © 2015 Kousuke Ohara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. B. Hoffman, A. Demakas, C. B. Erdman, M. Dimbil, and P. M. Doraiswamy, “Neuropsychiatric adverse effects of oseltamivir in the FDA adverse event reporting system, 1999–2012,” British Medical Journal, vol. 347, no. 7918, p. f4656, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Usami, T. Sasaki, N. Satoh et al., “Oseltamivir enhances hippocampal network synchronization,” Journal of Pharmacological Sciences, vol. 106, no. 4, pp. 659–662, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Surtees and C. DeSousa, “Influenza virus associated encephalopathy,” Archives of Disease in Childhood, vol. 91, no. 6, pp. 455–456, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Tanaka, Y. Sunden, Y. Sakoda, H. Kida, K. Ochiai, and T. Umemura, “Lipopolysaccharide treatment and inoculation of influenza A virus results in influenza virusassociated encephalopathylike changes in neonatal mice,” Journal of NeuroVirology, vol. 16, no. 2, pp. 125–132, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. V. D. Schmith and J. F. Foss, “Effects of inflammation on pharmacokinetics/pharmacodynamics: increasing recognition of its contribution to variability in response,” Clinical Pharmacology and Therapeutics, vol. 83, no. 6, pp. 809–811, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Morimoto, T. Nagami, N. Matsumoto et al., “Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats,” The Journal of Toxicological Sciences, vol. 37, no. 6, pp. 1217–1223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Ose, H. Kusuhara, K. Yamatsugu et al., “P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier,” Drug Metabolism and Disposition, vol. 36, no. 2, pp. 427–434, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Lu, C. Gonzales, Y. Chen et al., “CNS penetration of small molecules following local inflammation, widespread systemic inflammation or direct injury to the nervous system,” Life Sciences, vol. 85, no. 11-12, pp. 450–456, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Oshima, E. Nemoto, M. Kuramochi, Y. Saitoh, and D. Kobayashi, “Penetration of oseltamivir and its active metabolite into the brain after lipopolysaccharide-induced inflammation in mice,” The Journal of Pharmacy and Pharmacology, vol. 61, no. 10, pp. 1397–1400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Nishimura, G. A. Plotnikoff, and K. Watanabe, “Kampo medicine as an integrative medicine in Japan,” Japan Medical Association Journal, vol. 52, no. 3, pp. 147–149, 2009. View at Google Scholar · View at Scopus
  11. T. Kubo and H. Nishimura, “Antipyretic effect of Mao-to, a Japanese herbal medicine, for treatment of type A influenza infection in children,” Phytomedicine, vol. 14, no. 2-3, pp. 96–101, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Nabeshima, K. Kashiwagi, K. Ajisaka et al., “A randomized, controlled trial comparing traditional herbal medicine and neuraminidase inhibitors in the treatment ofseasonal influenza,” Journal of Infection and Chemotherapy, vol. 18, no. 4, pp. 534–543, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Mantani, T. Andoh, H. Kawamata, K. Terasawa, and H. Ochiai, “Inhibitory effect of Ephedrae herba, an oriental traditional medicine, on the growth of influenza A/PR/8 virus in MDCK cells,” Antiviral Research, vol. 44, no. 3, pp. 193–200, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Hayashi, N. Imanishi, Y. Kashiwayama et al., “Inhibitory effect of cinnamaldehyde, derived from Cinnamomi cortex, on the growth of influenza A/PR/8 virus in vitro and in vivo,” Antiviral Research, vol. 74, no. 1, pp. 1–8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Kurokawa, M. Tsurita, J. Brown, Y. Fukuda, and K. Shiraki, “Effect of interleukin-12 level augmented by Kakkon-to, a herbal medicine, on the early stage of influenza infection in mice,” Antiviral Research, vol. 56, no. 2, pp. 183–188, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. Ministry of Health, Labour, and Welfare, The Japanese Pahrmacopoeia, Ministry of Health, Labour and Welfare, 16th edition, 2011, http://jpdb.nihs.go.jp/jp16e/jp16e.pdf.
  17. S. Honma, H. Hirota, D. Kobayashi et al., “Comparison of drug between and detections of Chinese medicine as ethical pharmaceutics considering dispensing fee and contents of index ingredients,” Japanese Journal of Drug Informatics, vol. 5, no. 3, pp. 159–166, 2003. View at Google Scholar
  18. L. Balk, S. Månér, A. Bergstrand, W. Birberg, Å. Pilotti, and J. W. DePierre, “Preparation and characterization of subcellular fractions from the head kidney of the Northern pike (Esox lucius), with particular emphasis of xenobiotic-metabolizing enzymes,” Biochemical Pharmacology, vol. 34, no. 6, pp. 789–802, 1985. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Fuke, Y. Ihama, and T. Miyazaki, “Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu®,” Legal Medicine, vol. 10, no. 2, pp. 83–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. E. J. Kang, S. Major, D. Jorks et al., “Blood-brain barrier opening to large molecules does not imply blood-brain barrier opening to small ions,” Neurobiology of Disease, vol. 52, pp. 204–218, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Belayev, R. Busto, W. Zhao, and M. D. Ginsberg, “Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats,” Brain Research, vol. 739, no. 1-2, pp. 88–96, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Morimoto, M. Nakakariya, Y. Shirasaka et al., “Oseltamivir (Tamiflu) efflux transport at the blood-brain barrier via P-glycoprotein,” Drug Metabolism and Disposition, vol. 36, no. 1, pp. 6–9, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Morimoto, T. Nagami, N. Matsumoto et al., “Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats,” Journal of Toxicological Sciences, vol. 37, no. 6, pp. 1217–1223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Ose, M. Ito, H. Kusuhara et al., “Limited brain distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1- ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a Pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (OAT3/SLC22AS) and multidrug resistance-associated protein 4 (MRP4/ABCC4),” Drug Metabolism and Disposition, vol. 37, no. 2, pp. 315–321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Kurokawa, “Beneficial effect of Kakkon-to on nasal obstruction due to neurolepticus,” Kampo Medicine, vol. 43, no. 2, pp. 79–84, 1992. View at Google Scholar
  26. Y. Ozaki, “Studies on antiinflammatory effect of Japanese oriental medicines (Kampo medicines) used to treat inflammatory diseases,” Biological and Pharmaceutical Bulletin, vol. 18, no. 4, pp. 559–562, 1995. View at Publisher · View at Google Scholar · View at Scopus